Dynavax Technologies (DVAX) Expected to Announce Earnings on Tuesday

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) is expected to announce its Q1 2025 earnings results after the market closes on Tuesday, May 6th. Analysts expect Dynavax Technologies to post earnings of $0.03 per share and revenue of $70.01 million for the quarter.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.05 EPS for the quarter, meeting analysts' consensus estimates of $0.05. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. The company had revenue of $72.03 million during the quarter, compared to the consensus estimate of $72.70 million. On average, analysts expect Dynavax Technologies to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Dynavax Technologies Price Performance

Shares of NASDAQ:DVAX traded down $0.10 during midday trading on Friday, hitting $11.39. The company had a trading volume of 93,217 shares, compared to its average volume of 2,194,023. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34. Dynavax Technologies has a twelve month low of $9.74 and a twelve month high of $14.63. The business's 50-day simple moving average is $12.63 and its 200-day simple moving average is $12.58. The stock has a market cap of $1.39 billion, a price-to-earnings ratio of 63.31 and a beta of 1.26.

Analyst Upgrades and Downgrades

DVAX has been the topic of several research reports. The Goldman Sachs Group decreased their target price on Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating on the stock in a research note on Thursday, April 17th. HC Wainwright reissued a "buy" rating and issued a $31.00 price target on shares of Dynavax Technologies in a research report on Friday, February 21st. William Blair reiterated an "outperform" rating on shares of Dynavax Technologies in a research note on Friday, February 21st. Finally, StockNews.com raised Dynavax Technologies from a "hold" rating to a "buy" rating in a research note on Monday, February 24th.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.